Back to Authors

Atkins, Annette R

0000-0003-3583-4091

Mayo Clinic

Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037.

Citations 1

Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity
Wang, Liu , Oh, Tae Gyu , Magida, Jason A. , Estepa, Gabriela , Obayomi, S. M. Bukola , Yu, Ruth T. , Atkins, Annette R. , Hargreaves, Diana C. , Downes, Michael , Wei, Zong , Magida, Jason , Chong, Ling-Wa , Gatchalian, Jovylyn , Yu, Ruth T , Atkins, Annette R , Hargreaves, Diana , Downes, Michael , Wei, Zong , Evans, Ronald M , Evans, Ronald M.

Proceedings of the National Academy of Sciences | August 26, 2021 | Volume: 118 | Issue: 35 | Pages: No page available

10.1073/pnas.2109517118 Get It

Significance Glucocorticoids are widely prescribed antiinflammatory drugs that suppress inflammatory gene expression through activation of the glucocorticoid receptor (GR); however, the mechanisms of GR-mediated repression are not fully understood. We show here that bromodomain containing 9 (BRD9), a component of the SWI/SNF chromatin remodeling complex, modulates GR activity in bone marrow-derived macrophages. Loss of BRD9 activity in macrophages attenuated the response to liposaccharides and interferon inflammatory stimuli. Notably, BRD9 inhibition synergized with the synthetic glucocorticoid dexamethasone to suppress the inflammatory response in macrophages. Our data support a model in which BRD9 restricts GR binding at a subset of inflammatory related genes, and suggests that BRD9 inhibitors may increase the efficacy of glucocorticoids.